Stock JAGSNPHARM JAGSONPAL PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Jagsonpal Pharmaceuticals Limited

Equities

JAGSNPHARM

INE048B01027

Market Closed - NSE India S.E.
Other stock markets
 07:40:30 2024-07-09 am EDT 		5-day change 1st Jan Change
337 INR +1.86% Intraday chart for Jagsonpal Pharmaceuticals Limited +0.06% -13.33%
May. 24 Jagsonpal Launches Drug for Vasomotor Symptoms; Shares Jump 5% MT
May. 24 Jagsonpal Launches Memup India's First Bioidentical Hormone Replacement Therapy in A Single Pill CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Jagsonpal Launches Drug for Vasomotor Symptoms; Shares Jump 5%
MT
Jagsonpal Launches Memup India's First Bioidentical Hormone Replacement Therapy in A Single Pill
CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
CI
Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2024
CI
Jagsonpal Pharmaceuticals Limited agreed to acquire India & Bhutan business of Yash Pharma Laboratories Private Limited from Yash Pharma Laboratories Private Limited for approximately INR 930 million.
CI
Jagsonpal Pharmaceuticals Limited Launches Queezy-ER®
CI
Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes
CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Ex-dividend day for final dividend
FA
Jagsonpal Pharmaceuticals' Net Profit Soars in Fiscal Q1
MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
CI
Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023
CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others completed the acquisition of 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar.
CI
Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer
CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes
CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
CI
Jagsonpal Pharmaceuticals : ESOP/ESPS/SBEB Scheme
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAGSNPHARM Stock
  4. News Jagsonpal Pharmaceuticals Limited